1. 2700 Final results of ARIEL2 (Part 1): A phase 2 trial to prospectively identify ovarian cancer (OC) responders to rucaparib using tumor genetic analysis. Issue 3 (September 2015) Authors: Kristeleit, R.; Swisher, E.; Oza, A.; Coleman, R.L.; Scott, C.; Konecny, G.; Tinker, A.; O'Malley, D.M.; Brenton, J.; Bell-McGuinn, K.; Oaknin, A.; Leary, A.; Lin, K.K.; Raponi, M.; Giordano, H.; Maloney, L.; Goble, S.; Yelensky, R.; McNeish, I. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S531 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 2701 Quantification of genomic loss of heterozygosity enables prospective selection of ovarian cancer patients who may derive benefit from the PARP inhibitor rucaparib. (September 2015) Authors: Lin, K.; Sun, J.; Maloney, L.; Goble, S.; Oza, A.; Coleman, R.; Scott, C.; Robillard, L.; Mann, E.; Isaacson, J.; Harding, T.; Giordano, H.; Rolfe, L.; McNeish, I.; Swisher, E.; Yelensky, R.; Allen, A.; Raponi, M. Journal: European journal of cancer Issue: Volume 51:(2015)Supplement 3 Page Start: S531 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Feasibility of monitoring response to the PARP inhibitor rucaparib with targeted deep sequencing of circulating tumor DNA (ctDNA) in women with high grade ovarian carcinoma on the ARIEL2 trial. (December 2016) Authors: Piskorz, A.M.; Lin, K.K.; Morris, J.; Mann, E.; Oza, A.; Coleman, R.L.; O'Malley, D.M.; Friedlander, M.; Cragun, J.M.; Ma, L.; Giordano, H.; Raponi, M.; McNeish, I.A.; Swisher, E.; Brenton, J.D. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Integrated efficacy and safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with high-grade ovarian carcinoma (HGOC). (February 2017) Authors: Oaknin, A.; Oza, A.; Tinker, A.V.; Ray-Coquard, I.; Coleman, R.; O'Malley, D.; Shapira-Frommer, R.; Leary, A.; Chen, L.M.; Provencher, D.; Ma, L.; Brenton, J.; Balmaña, J.; Giordano, H.; Maloney, L.; Goble, S.; Rolfe, L.; McNeish, I.; Swisher, E.; Kristeleit, R.S. Journal: European journal of cancer Issue: Volume 72(2017)Supplement 1 Page Start: S95 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Secondary mutations in RAD51C and RAD51D are associated with acquired resistance to the PARP inhibitor rucaparib in patients with high-grade ovarian cancer. (December 2016) Authors: Lin, K.; Tinker, A.V.; Kondrashova, O.; Ho, G.; Wakefield, M.; Coleman, R.L.; O'Malley, D.M.; Floquet, A.; Sun, J.; Maloney, L.; Giordano, H.; Harding, T.; Raponi, M.; McNeish, I.A.; Swisher, E.; Scott, C.L. Journal: European journal of cancer Issue: Volume 69(2016)supplement 1 Page Start: S13 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗